The deadliest cancers are receiving a fraction of the funding per death
Every year, tens of thousands of Americans die from pancreatic and small-cell lung cancers that medicine has barely learned to slow — yet federal research dollars flow most generously toward cancers that most patients survive. A study published in JAMA Network Open reveals that NIH funding per death for pancreatic cancer is roughly fourteen times lower than for prostate cancer, a disparity shaped less by scientific logic than by decades of advocacy, infrastructure, and philanthropic momentum. The question it leaves behind is an old and difficult one: in a world of finite resources, how do we decide whose suffering deserves the most urgent attention?
- Pancreatic and small-cell lung cancers kill the vast majority of those they touch, yet receive as little as $2,818 per death in NIH research funding — a fraction of what survivable cancers command.
- Prostate cancer, with fewer than one in ten diagnoses ending in death, receives $126,992 per death, exposing a funding landscape shaped by history rather than clinical urgency.
- The disparity compounds over time: as well-funded cancers accumulate breakthroughs and infrastructure, underfunded ones fall further behind, widening the gap in what medicine can actually offer patients.
- Private industry investment follows incidence rather than mortality, meaning the cancers most likely to kill are also least likely to attract commercial research interest.
- Researchers are calling for a composite federal framework that weighs incidence, survival, and mortality together — a structural correction to a system that has quietly drifted away from those most in need.
The numbers tell a story of misalignment. Pancreatic cancer kills nearly 50,000 Americans a year, and small-cell lung cancer kills another 9,700 — yet both receive a fraction of the NIH research funding per death that far more survivable cancers command. A study published in JAMA Network Open analyzed funding across nine major cancer types and found the disparity stark: pancreatic cancer receives $8,945 per estimated death, small-cell lung cancer just $2,818, while prostate cancer — with a mortality-to-incidence ratio below 0.1 — receives $126,992 per death, and breast cancer $69,800.
In raw dollars, breast cancer research received $1.58 billion in 2025 NIH funding, prostate cancer $662 million. Pancreatic cancer received $440 million despite its lethality; small-cell lung cancer received just $62 million. The researchers are careful to note this reflects accumulated decisions over decades — breast and prostate cancer research benefited from sustained advocacy, early therapeutic breakthroughs, and entrenched infrastructure that perpetuates itself. Cancers with less public visibility depend more heavily on federal dollars, and when those dollars are limited, the imbalance widens. Private industry compounds the problem by tracking incidence rather than mortality.
What makes the finding urgent is what it implies for the future. Pancreatic and small-cell lung cancers have mortality-to-incidence ratios exceeding 0.85 — most people diagnosed will die. As outcomes for breast and prostate cancer continue to improve through accumulated investment, the knowledge gap between these diseases and the deadliest cancers will only grow. The researchers propose a composite federal framework weighing incidence, survival, and mortality together, acknowledging that a cancer affecting 50,000 people with 85 percent mortality represents a fundamentally different public health challenge than one most patients survive. The current system, they argue, has drifted so far from clinical need that rebalancing is overdue — and for those facing a pancreatic cancer diagnosis today, the cost of that drift is already being paid.
The numbers tell a story of misalignment. Pancreatic cancer kills nearly 50,000 Americans a year. Small-cell lung cancer kills another 9,700. Yet when researchers at the National Cancer Institute examined how the National Institutes of Health distributes its research dollars, they found something troubling: the deadliest cancers are receiving a fraction of the funding per death compared to cancers with far better survival rates.
The study, published in JAMA Network Open, analyzed NIH funding across nine major cancer types and cross-referenced it against incidence, survival, and mortality data. The disparity is stark. Pancreatic cancer receives $8,945 per estimated death. Small-cell lung cancer receives $2,818 per death. By contrast, prostate cancer—which has a mortality-to-incidence ratio below 0.1, meaning most diagnoses do not result in death—receives $126,992 per death. Breast cancer, similarly survivable, receives $69,800 per death.
The raw funding numbers underscore the gap. Breast cancer research received $1.58 billion in 2025 NIH funding. Prostate cancer received $662 million. Pancreatic cancer, despite its lethality, received $440 million. Small-cell lung cancer received just $62 million. When you calculate funding per incident case, the picture shifts slightly but remains revealing: ovarian cancer, with relatively good survival outcomes, receives $20,945 per case, while small-cell lung cancer receives $2,562.
The researchers note that this pattern reflects decades of accumulated decisions rather than a single policy choice. Breast and prostate cancer research benefited from sustained advocacy, from therapeutic breakthroughs that attracted further investment, and from established research infrastructure that perpetuates itself. Cancers with less public visibility or philanthropic support depend more heavily on federal dollars, and when those dollars are limited, the imbalance widens. Private industry investment often tracks incidence rather than mortality, reinforcing the same skew.
What makes this finding urgent is what it implies about future progress. Pancreatic cancer and small-cell lung cancer have mortality-to-incidence ratios exceeding 0.85—meaning most people diagnosed will die from the disease. These are not rare cancers. They are common killers. Yet they receive research funding that suggests they are afterthoughts. As outcomes for breast and prostate cancer continue to improve through accumulated research investment, the gap between what we know about treating these cancers and what we know about treating pancreatic or small-cell lung cancer will only widen.
The researchers propose a composite federal funding framework that would weigh incidence, survival rates, and mortality together rather than relying on any single metric. Such a framework would acknowledge that a cancer affecting 100,000 people with a 95 percent survival rate represents a different public health challenge than a cancer affecting 50,000 people with an 85 percent mortality rate. The authors are careful to note that burden alone cannot capture scientific opportunity or feasibility—some research directions may be more promising than others regardless of disease prevalence. But the current system, they argue, has drifted so far from clinical need that rebalancing is overdue.
The study examined only one fiscal year of funding data and relied on estimated rather than observed mortality counts, limitations the authors acknowledge. Yet the pattern is clear enough to raise hard questions about how research priorities are set and whether they still serve the patients most in need. For people facing a pancreatic cancer diagnosis, the answer appears to be no.
Citas Notables
The most lethal cancers received disproportionately lower federal funding, and prioritizing resources toward such cancers could help decrease suffering as outcomes for less lethal cancers continue to improve.— Study authors, National Cancer Institute
La Conversación del Hearth Otra perspectiva de la historia
Why does funding lag so far behind lethality? Is it just inertia?
Partly, yes. But it's also that success breeds more success. Breast cancer research got a boost from advocacy movements decades ago, and that created infrastructure—labs, networks, trained researchers. Money follows momentum.
So the system is self-reinforcing.
Exactly. Private companies invest in cancers where there's already a market and research base. Federal funding then fills gaps, but those gaps are already shaped by where private money went. Pancreatic cancer has neither the advocacy nor the industry attention, so it depends almost entirely on federal dollars that aren't there.
The mortality-to-incidence ratio is the key metric here, isn't it?
It's one of them. Pancreatic cancer kills 85 percent of people diagnosed. Prostate cancer kills maybe 5 percent. That's a fundamental difference in clinical urgency, but the funding doesn't reflect it.
What would actually change if they adopted this composite framework?
It would force a conversation about reallocation. You can't suddenly triple pancreatic cancer funding without taking from somewhere else. That's politically hard, especially when breast cancer advocacy groups have built real power.
Is there any chance this happens?
The researchers are careful not to oversell it. They know burden alone doesn't determine where breakthroughs are possible. But the gap is so wide now that some shift seems inevitable. The question is whether it happens through policy or through crisis.